☆ 4.7 Letter

Early clinical experience with imatinib in COVID-19: Searching for a dual effect

JOURNAL OF INFECTION (2021)

Related references

Note: Only part of the references are listed.

Article Multidisciplinary Sciences

Identification of SARS-CoV-2 inhibitors using lung and colonic organoids

Yuling Han et al.

Summary: Researchers have developed lung and colonic organoid models using human pluripotent stem cells, which demonstrate susceptibility to SARS-CoV-2 infection. These models are valuable for studying the infection of the virus and screening drugs, with potential therapeutic implications for COVID-19.

NATURE (2021)

Add to Collection

Editorial Material Critical Care Medicine

Immunomodulation in COVID-19

Nicholas E. Ingraham et al.

LANCET RESPIRATORY MEDICINE (2020)

Add to Collection

Letter Oncology

Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey

Massimo Breccia et al.

LEUKEMIA (2020)

Add to Collection

Letter Immunology

Imatinib for COVID-19: A case report

Alejandro Morales-Ortega et al.

CLINICAL IMMUNOLOGY (2020)

Add to Collection

Letter Oncology

Imatinib is not a potent anti-SARS-CoV-2 drug

Helong Zhao et al.

LEUKEMIA (2020)

Add to Collection

Article Virology

Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion

Christopher M. Coleman et al.

JOURNAL OF VIROLOGY (2016)

Add to Collection

Article Physiology

Imatinib attenuates inflammation and vascular leak in a clinically relevant two-hit model of acute lung injury

Alicia N. Rizzo et al.

AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2015)

Add to Collection

© Peeref 2019-2024. All rights reserved.